Berger Montague Begins Investigation into Akero Therapeutics for Possible Breaches of Duty

Berger Montague Investigates Akero Therapeutics

Philadelphia, November 12, 2025 - Berger Montague PC has recently announced an investigation into Akero Therapeutics, Inc. and its board of directors. This inquiry focuses on potential breaches of fiduciary duties and violations of federal securities laws. Shareholders of Akero are urged to stay updated regarding this situation and can contact Berger Montague directly for further details.

Context of the Investigation

Located in San Francisco, Akero is a clinical-stage biopharmaceutical company developing efruxifermin (EFX), a drug targeted for treating metabolic dysfunction-associated steatohepatitis (MASH). The potential investigation is rooted in a recent announcement about a proposed merger with Novo Nordisk A/S. On October 9, 2025, it was revealed that Akero shareholders could receive $54.00 per share, along with a Contingent Value Right that might provide an additional $6.00 per share if efruxifermin gains regulatory approval by June 30, 2031.

The announcement has raised concerns among shareholders regarding the appropriateness and implications of this merger and whether the board has fully honored their fiduciary responsibilities to the investors. Berger Montague's investigation aims to clarify if there have been any violations or misconduct during the merger discussions.

Shareholder Rights and Options

For shareholders who are interested in the investigation or possible legal action, Berger Montague invites them to reach out. Shareholders may contact Andrew Abramowitz at [email protected] or call (215) 875-3015, or Radha Raghavan at [email protected] or (215) 875-4698 for more information about their rights and what steps to take next.

Berger Montague has a longstanding reputation for representing investors, having been a pioneer in securities class action litigation since its inception in 1970. They have handled numerous cases across various courts in the United States and are known for their commitment to protecting the interests of shareholders.

The Future of Akero and Shareholder Interests

With the merger part of a critical juncture for Akero Therapeutics, the proceedings of this investigation will be pivotal in determining whether the interests of shareholders are adequately safeguarded. As developments unfold regarding the merger with Novo Nordisk and the potential implications for the company's future, shareholders must remain vigilant and informed about their options.

In conclusion, Berger Montague's probing into Akero Therapeutics serves as a reminder of the importance of corporate governance and the need for boards to uphold their fiduciary duties. It highlights the potential risks involved in significant corporate transactions and the necessity for transparency and accountability in all dealings with shareholders.

As the situation develops, investors should maintain an active dialogue with legal counsel and stay updated on any new information that might arise regarding this matter.